Across TCGA pan-cancer cohorts, ARHGAP30 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP30 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARHGAP30 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP30 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where ARHGAP30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.765	0.514	.005	9	view →
PDAC	DFS	Quartile	All	0.987	0.715	.008	8	view →
GBM	OS	Tertile	All	0.338	0.640	.001	6	view →
HNSC	DFS	Quartile	III,IV	0.855	0.355	.036	2	view →
CCRCC	DFS	Quartile	II,III,IV	0.866	0.578	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ARHGAP30 tumor-vs-normal RNA expression · all ARHGAP30 data types